Sopharma Group has acquired two pharmaceutical products in Poland
Sopharma Group has acquired Coffepirine and Kopiryna, two highly recognized medicines to treat headache. The acquisition will further expand the market presence of Sopharma Group in the Polish market and support the promising potential of the two pharmaceutical drugs.
Sopharma Group is a leading producer and distributor of healthcare products in the CEE, with a vertically integrated business model running through the whole value chain, with its own R&D, manufacturing and wholesale and retail distribution. The company is present in 33 countries and has a portfolio consisting of more than 200 products.
Coffepirine and Kopiryna are OTC analgesics with APIs based on a combination of acetylsalicylic acid and caffeine, which have helped the Polish public to treat headaches for decades. The drugs are developed and manufactured by Medicofarma, a well-known Polish pharmaceuticals company.
Medicofarma is a pharmaceutical manufacturing company focusing on contract manufacturing of pharmaceuticals, medicinal products and dietary supplements. The company has a modern factory equipped with state-of-the-art technology and meets all GMP requirements.
Oaklins’ team in Bulgaria acted as buy-side advisor to Sopharma Group, leading the transaction process, deal structuring and negotiations, and assisting throughout the acquisition process.
联系交易团队
相关交易
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
更多信息Phen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
更多信息Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
更多信息